Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Silibinin is a suppressor of the metastasis-promoting transcription factor ID3.
Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA. Verdura S, et al. Among authors: teixidor e. Phytomedicine. 2024 Mar 6;128:155493. doi: 10.1016/j.phymed.2024.155493. Online ahead of print. Phytomedicine. 2024. PMID: 38484626 Free article.
Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J. Teixidor E, et al. Oncotarget. 2023 Jul 1;14:668. doi: 10.18632/oncotarget.28471. Oncotarget. 2023. PMID: 37395727 Free PMC article. No abstract available.
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N; RENACER; Valiente M. Monteiro C, et al. Among authors: teixidor e. Nat Med. 2022 Apr;28(4):752-765. doi: 10.1038/s41591-022-01749-8. Epub 2022 Apr 11. Nat Med. 2022. PMID: 35411077 Free PMC article.
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA. Bosch-Barrera J, et al. Among authors: teixidor e. Pharmaceuticals (Basel). 2021 Dec 24;15(1):19. doi: 10.3390/ph15010019. Pharmaceuticals (Basel). 2021. PMID: 35056076 Free PMC article.
Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J. Teixidor E, et al. Oncotarget. 2018 Aug 31;9(68):33043-33049. doi: 10.18632/oncotarget.25984. eCollection 2018 Aug 31. Oncotarget. 2018. PMID: 30250648 Free PMC article.